Sudden death during flecainide therapy for atrial fibrillation complicating Wolff-Parkinson-white syndrome

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 1, Issue 2, 1996, Pages 159-164

  Chun, Sung ^a,b,c   Singh, Bramah N ^a,b,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33747370885     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/107424849600100210     Document Type: Article

References (43)

1. Gallagher JJ, Pritchett ELC, Sealy WC, Kasell J, Wallace AG. The preexcitation syndromes. Prog Cardiovasc Dis 20:285, 1977.
2. Josephson ME, Kastor JA. Supraventricular tachycardia: Mechanisms and management. Ann Intern Med 187:346, 1977.
3. Wellens HJJ, Durrer D. Wolff-Parkinson-White syndrome and atrial fibrillation. Am J Cardiol 344:777, 1974.
4. Schluter M. Geiger M, Siebels J, Duckeck W, Kuck KH. Catheter ablation using radiofrequency current to cure symptomatic patients with tachyarrhythmias related to an accessory atrioventricular pathway. Circulation 84:1644, 1991.
5. Sharma AD, Klein GJ, Guiraudor GM, Milstein S. Atrial fibrillation in patients with Wolff-Parkinson-White syndrome: Incidence after surgical ablation of the accessory pathyway. Circulation 72:161, 1985.
6. Feld GK, Nademanee K, Stevenson W, Weiss J, Klitzner T, Singh BN. Clinical and electrophysiologic effects of amiodarone in patients with atrial fibrillation complicating the Wolff-Parkinson-White Syndrome. Am Heart J 115:102, 1988.
7. Feld GK, Nademanee K, Weiss J, Stevenson WV, Singh BN. Electrophysiologic basis for the suppression by amiodarone of orthodromic supraventricular tachycardia complicating preexcitation syndromes. J Am Coll Cardiol 3:1298, 1984.
8. Podrid PJ, Lown B. Amiodarone in symptomatic sustained refractory atrial and ventricular tachyarrhythmias. Am Heart J 101:374, 1981.
9. Rowland E, Krikler DM. Electrophysiologic assessment of amiodarone in treatment of resistant supraventricular arrhythmias. Am J Cardiol 44:82, 1980.
10. Chamberlain DA, Clark ANG. Atrial fibrillation complicating Wolff-Parkinson-White syndrome treated with amiodarone. B M J 60:1519, 1977.
11. Morady F, DiCarlo LA, Krol RB, Baerman JM, DeBuitler M. Acute and chronic effects of amiodarone on ventricular refractoriness, intraventricular conduction and ventricular tachycardia induction. J Am Coll Cardiol 7:145, 1986.
12. Yabek S, Kato R, Singh BN. Effects of amiodarone and its metabolite, desethylmiodarone, on the electrophysiologic properties of isolated cardiac muscle. J Cardiovasc Pharmacol 8:197, 1976.
13. Kappenberger LJ, Fromer MA, Steinbrunn W, Shenasa M. Efficacy of amiodarone in the Wolff-Parkinson-White syndrome with rapid ventricular response via accessory pathway during atrial fibrillation. Am J Cardiol 54:33, 1984.
14. Kappenberger LJ, Fromer MA, Shenasa M, Gloor HO. Evaluation of flecainide acetate in rapid atrial fibrillation complicating Wolff-Parkinson-White syndrome. Clin Cardiol 8:321, 1985.
15. Manolis AS, Salem DN, Estes III NAM. Electrophysiologic effects, efficacy and tolerance of class Ic antiarrhythmic agents in Wolff-Parkinson-White syndrome. Am J Cardiol 63:746, 1989.
16. Nathan AW, Camm AJ, Bexton RS, Hellestrand KJ. Intravenous flecainide acetate for the clinical management of paroxysmal tachycardias. Clin Cardiol 10:317, 1987.
17. Chouty F, Coumel P. Oral flecainide for prophylaxis of paroxysmal atrial fibrillation. Am J Cardiol 62:335D, 1988.
18. Anderson JL, Jolivette DM, Fredell PA. Summary of efficacy and safety of flecainide for supraventricular arrhythmias. Am J Cardiol 62:62D, 1988.
19. Hellestrand KJ, Bexton RS, Nathan AW, Spurrell RAJ, Camm AJ. The acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man. Br Heart J 48:140, 1982.
20. Hellestrand KJ. Nathan AW, Bexton RS, Spurrell RAJ, Camm AJ. Cardiac electrophysiologic effects of flecainide acetate for paroxysmal reentrant junctional tachycardias. Am J Cardiol 51:770, 1983.
21. Wang Z. Pelletier LC, Talajic M, Nattel S. Effects of flecainide and quinidine on human atrial action potentials: Role of rate-dependence and comparison with guinea pig, rabbit, and dog tissues. Circulation 1982:274, 1990.
22. Special report: Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New Engl J Med 321:406, 1989.
23. Falk RH. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med 111:107, 1989.
24. Morganroth J, Horowitz LN. Flecainide: Its proarrhythmic effect and expected changes on the surface electrocardiogram. Am J Cardiol 53:89B, 1984.
25. Feld GK, Chen PS, Nicod P, Fleck P, Meyer D. Possible atrial proarrhythmic effects of class IC antiarrhythmic drugs. Am J Cardiol 66:378, 1990.
26. Marcus FI. The hazards of using type IC antiarrhythmic drugs for the treatment of paroxysmal atrial fibrillation. Am J Cardiol 66:366, 1990.
27. Sihm I, Hansen A, Rasmussen J, Pedersen AK, Thygesen K. Flecainide acetate in atrial flutter and fibrillation: The arrhythmogenic effects. Eur Heart J 11:145, 1990.
28. Nathan AW, Hellestrand KJ, Bexton RS, Banium SO, Spurrell RAJ, Camm AJ. Proarrhythmic effects of the new antiarrhythmic agent flecainide acetate. Am Heart J 107:222, 1984.
29. Herre JM, Titus C, Oeff M, Eldar M, Eldar MR, Griffin JC, Scheinman MM. Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation. Ann Intern Med 113:671, 1990.
30. Pritchett ELC, Wilkinson WE. Mortality in patients treated with flecainide and encainide for supnventricular arrhythmias. Am J Cardiol 67:976, 1991.
31. Rosen MR. Wit AL. Arrhythmogenic actions of antiarrhythmic drugs. Am J Cardiol 59:10E, 1987.
32. Hondeghem LM. Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Circulation 81:686, 1990.
33. Singh BN, Nademanee K. Sotalol: A beta blocker with unique antiarrhythmic properties. Am Heart J 114:121, 1987.
34. Touboul P, Atallah G, Kirkorian G, Lamaud M, Moleur P. Clinical electrophysiology of intravenous sotalol, a beta-blocking drug with class III antiarrhythmic properties. Am Heart J 107:888, 1984.
35. Nathan AW, Hellestrand KJ, Bexton RS, Ward DE, Spurrell RAJ, Camm AJ. Electrophysiological effects of sotalol: Just another beta blocker? Br Heart J 47:515, 1982.
36. Singh BN. Historical development of the concept of controlling carrdiac arrhythmias by lengthening repolarization: Particular reference to sotalol. Am J Cardiol 65:3A, 1990.
37. Nademanee K, Singh BN. Effects of sotalol on ventricular tachycardia and fibrillation produced by programmed electrical stimulation: Comparison with other antiarrhythmic agents. Am J Cardiol 65:53A, 1990.
38. Strauss HC, Bigger JT, Hoffman BE. Electrophysiological and beta-receptor blocking effects of MJ 1999 on dog & rabbit cardiac tissue. Circ Res 26:661, 1970.
39. Singh BN, Vaughan Williams EM. A third class of antiarrhythmic action: Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of JM 1999 and AH 3474. Br J Pharmacol 39:675, 1970.
40. Edvardsson N, Hirsch I, Emanuelsson H, Ponka J, Olsson SB. Sotalol induced delayed ventricular repolarization in man. Eur Heart J 1:335, 1980.
41. Anderson KP, Walker R, Dustman T, Lux RL, Ershler PR, Kales RE, Urie PM. Rate-related electrophysiologic effects of long-term administration of amiodarone on canine ventricular myocardium in vivo. Circulation 79:948, 1989.
42. Singh BN, Ahmed R. Class III antiarrhythmic drugs. Curr Opin Cardiol 19:12, 1993.
43. Anastasiou-Nana MI, Anderson JL, Stewart JR, Cresey BJ, Yanowitz FG, Lutz JR, Johnson TA. Occurrence of exercise induced and spontaneous wide complex tachycardia during therapy with flecainide for complex ventricular arrhythmias: A probable proarrhythmic effect. Am Heart J 113:1071, 1987.